Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUSRE34712 E
Publication typeGrant
Application numberUS 08/122,009
Publication dateAug 30, 1994
Filing dateSep 14, 1993
Priority dateJun 14, 1988
Fee statusPaid
Also published asCA1339452C, DE10399030I1, DE10399030I2, DE68921672D1, DE68921672T2, EP0347066A1, EP0347066B1, US4943590
Publication number08122009, 122009, US RE34712 E, US RE34712E, US-E-RE34712, USRE34712 E, USRE34712E
InventorsKlaus P. Boegesoe, Jens K. Perregaard
Original AssigneeH. Lundbeck A/S
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroiso benzofuran-5-carbonitrile and non-toxic acid addition salts thereof
US RE34712 E
Abstract
The two enantiomers of the anti-depressant drug of the formula I ##STR1## are disclosed. Methods for resolving intermediates and their .[.steroselective.]. .Iadd.stereoselective .Iaddend.conversion to a corresponding .[.enatiomer.]. .Iadd.enantiomer .Iaddend.of I are also disclosed.
Images(9)
Previous page
Next page
Claims(12)
We claim:
1. A compound selected from substantially pure (+)-1-(3-Dimethylaminopropyl)-1-(4'- fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile and non-toxic acid addition salts thereof.
2. A compound of claim 1 being .Iadd.the .Iaddend.pamoic acid salt of substantially pure (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile.
3. A pharmaceutical composition in unit dosage form comprising a pharmaceutically acceptable diluent or adjuvant and, as an active ingredient, a compound as defined in claim 1.
4. A pharmaceutical composition in unit dosage form comprising a pharmaceutically acceptable diluent or adjuvant and, as an active ingredient, the compound of claim 2.
5. A pharmaceutical composition in unit dosage form, according to claim 3, wherein the active ingredient is present in an amount from 0.1 to 100 milligram per unit dose.
6. A pharmaceutical composition in unit dosage form, according to claim 4, wherein the active ingredient is present in an amount from 0.1 to 100 milligram per unit dose.
7. A method for the alleviation of depression in a living animal body subject thereto which comprises the step of administering to the living animal body an amount of a compound of claim 1 which is effective for said purpose.
8. A method for the alleviation of depression in a living animal body subject thereto which comprises the step of administering to the living animal body an amount of a compound of claim 2 which is effective for said purpose.
9. Method of claim .[.10.]. .Iadd.7 .Iaddend.wherein the compound is administered in the form of a pharmaceutical composition thereof.
10. Method of claim 8 wherein the compound is administered in the form of a pharmaceutical composition thereof.
11. A method for the preparation of a compound as defined in claim 1, which comprises, converting substantially, pure .[.(+)-4-(4-dimethylamino)-1-(4'-fluorophenyl)-1-(hydroxybutyl)-3-(hydroxymethyl)-benzonitrile.]. .Iadd.(-)-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxy-1-butyl]-3-(hydroxymethyl)-benzonitrile .Iaddend.or a .[.monomester.]. .Iadd.monoester .Iaddend.thereof in a stereoselective way to substantially pure (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile which is isolated as such or as a non-toxic acid addition salt thereof.
12. A compound of the formula .Iadd.(31)-Enantiomer of the compound 4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxy-1-butyl]-3-(hydroxymethyl)-benzonitrile or an ester of said (-)enantiomer, which has the formula .Iaddend. ##STR6## wherein R is hydrogen or represents a group completing a labile ester.
Description

The present invention relates to the two novel enantiomers of the antidepressant drug 1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-.[.dihydroisobenzofuran.]. .Iadd.dihydroisobenzofuran.Iaddend.-b 5-carbonitrile (citalopram) of the following formula I: ##STR2## and to the use of these enantiomers as antidepressant compounds as well as the possible use as geriatrics or in the cure of obesity or alcoholism.

This invention also includes pharmaceutically acceptable salts of the enantiomers of compound I formed with non-toxic organic or inorganic acids. Such salts are easily prepared by methods known to the art. The base is reacted with either the calculated amount of organic or inorganic acid in an aqueous miscible solvent, such as acetone or ethanol, with isolation of the salt by concentration and cooling or an excess of the acid in aqeuous immiscible solvent, such as ethyl ether, ethyl acetate or .[.dicloromethane.]. .Iadd.dichloromethane.Iaddend., with the desired salt separating directly. Exemplary of such organic .].salt.]. .Iadd.salts .Iaddend.are those with maleic, fumaric, benzoic, ascorbic, pamoic, succinic, oxalic, salicylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-amino-benzoic, glutamic, benzene sulfonic and theophylline acetic acid, as well as the 8-halotheophyllines, for example 8-bromotheophylline.

Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids. Of course, these salts may also be prepared by the conventional method of double decomposition of appropriate salts, which is well-known to the art.

Furthermore it was found that non-hygroscopic acid addition salts might be obtained by .[.conventinal.]. .Iadd.conventional .Iaddend.freeze drying techniques from water solutions of appropriate salts of the above mentioned kinds.

The invention is also concerned with a method to resolve the intermediate racemate and to produce the individual isomers of I therefrom.

BACKGROUND OF THE INVENTION

Citalopram, which has been disclosed in e.g. U.S. Pat. No. 4,136,193, has proven to be an efficient antidepressant compound in man (Ref.: A. Gravem et. al., Acta pysychiat. Scan., No. 75, p. 478-486 (1987). All work in the development of this compound has been made with the racemate. Citalopram has been shown pharmacologically to be a very selective inhibitor of 5-HT reuptake. Previous attempts to crystallize diastereomeric salts of citalopram enantiomers have failed.

SUMMARY OF THE INVENTION

Surprisingly, it has now proven possible to resolve the intermediate .[.4-(4-dimethylamino)-1-(4'-fluorophenyl)-1-(hydroxybutyl)-3-(hydroxymethyl)benzonitrile.]. .Iadd.4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxy-1-butyl]-3-(hydroxymethyl)-benzonitrile.Iaddend., II, into its enantiomers and finally in a stereoselective way to convert these enantiomers to the corresponding citalopram enantiomers. Likewise, monoesters of II formed by optically active carboxylic acids could be separated into the corresponding diastereomers and subsequently converted directly into citalopram enantiomers in a steroselective ringclosure reaction. The intermediate diol, II, has been disclosed in e.g. U.S. Pat. No. 4,650,884 as a racemic mixture. ##STR3##

The enantiomers of the intermediate of formula II as well as monoesters fall likewise within the scope of the present invention.

Furthermore, it was shown to our surprise that almost the entire 5-HT uptake inhibition resided in the (+)-citalopram enantiomer.

The present invention also includes a new method of synthesizing I from the diol compound II by esterification of the primary alcohol group into a labile ester, which in the presence of a base undergoes spontaneous ringclosure to citalopram or, if enantiomerically pure II is esterified, the corresponding citalopram enantiomer is produced with fully conservation of stereoconfiguration.

According to the invention, II is reacted with:

(a) an enantiomerically pure acid derivative as an acid chloride, anhydride or .[.libile.]. .Iadd.labile .Iaddend.ester as e.g. .[.examplified.]. .Iadd.exemplified .Iaddend.in reaction scheme I by (+)- or (-) -α-methoxy-α-trifluoromethylphenylacetyl chloride. The reaction is preferably performed in an inert organic solvent as e.g. toluene, dichloromethane or tetrahydrofuran. A base (triethylamine, N,N-dimethylaniline, pyridin or the like) is added to neutralize liberated HCl. The diastereoisomers are subsquently separated by HPLC or fractional crystallization. The thus purified .[.disatereoisomers.]. .Iadd.diastereoisomers.Iaddend.are .[.finnaly.]. .Iadd.finally .Iaddend.separately treated with strong base (e.g. alkoxide) in an inert organic solvent as e.g. toluene, tetrahydrofuran, or dimethoxyethane yielding the pure citalopram enantiomers respectively. The ringclosure reaction is preferably performed at relatively low temperatures (-20 C.) to room temperature). ##STR4## (b) the enantiomers of an optically active acid successively affording the pure diastereomeric salts. Optically antipodes of tartaric acid, di-benzoyltartaric acid, di-(p-.[.toloyl.]. .Iadd.toluoyl.Iaddend.)tartaric acid, bisnaphthylphosphoric acid, 10-camphorsulphonic acid and the like are conveniently used.

(c) Stereoselective ringclosure of the pure enantiomers of II prepared as in (b) is performed via a labile ester as e.g. methansulfonyl, p-toluenesulfonyl, 10-camphorsulfonyl, trifuoracetyl or trifluoromethansulfonyl with simultaneous addition of a base (triethylamine, dimethylaniline or pyridin) in an inert organic solvent at 0 C. The ringclosure reaction is .[.examplified.]. .Iadd.exemplified .Iaddend.in reaction scheme II: ##STR5##

EXAMPLE 1 Resolution by method (a)

To 11 g of (+)-α-methoxy-α-trifluoromethylacetic acid dissolved in 25 ml of chloroform were added 50 ml of thionylchloride and a few drops of dimethylformamide. The reaction mixture was refluxed for 2 hours. Excess of thionylchloride was evaporated with toluene leaving the (+)-α-methoxy-α-trifluoromethylacetyl chloride as a liquid. This liquid diluted with 50 ml of dichloromethane was added dropwise to an ice cooled solution of 17 gr of .[.4-(4-dimethylamino-1-(4'-fluorophenyl)-1-hydroxybutyl)-3-(hydroxymethyl)-benzonitrile.]. .Iadd.4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxy-1-butyl]-3-(hydroxymethyl)-benzonitrile.Iaddend., II, and 8 ml of triethylamine in 150 ml of dichloromethane. The reaction mixture was further stirred for another hour at room temperature, subsequently washed with brine, dried (MgSO4) and the solvent evaporated below 30 C. in vacuo affording 29 gr of the ester as a diastereomeric mixture. By repeated HPLC purification (eluted with ethyl acetate/tetrahydrofuran 9:1 containing 4% of triethylamine) and by collecting only the 5-10% initial substance in the main peak, 1.1 gr of enantiomerically pure compound was isolated.

The substance thus isolated was dissolved in dry toluene (50 ml) and added to a suspension of 0.3 gr of potassium t-butoxide in 20 ml of toluene at 0 C. The toluene solution was washed with water, dried (MgSO4) and the solvent evaporated yielding 0.6 gr of (+)-1-(dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile as an oil. [α]D =+11.81 (c=1, CH3 OH) (determined with a substance containing 10% w/w of methanol). The optical purity was determined by 1 H NMR spectroscopy (CDCL3 as solvent) (Bruker AC-250 MHz instrument) by addition of a 10:1 w/w surplus of the chiral reagent (-)-2,2,2-trifluoro-1-(9-anthryl)ethanol. Optical purity: 99.6%.

In a totally analogous way the (-)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile was synthesized. [α]D =-12.34 (c=1, CH3 OH) (determined with a substance containing 10% w/w of methanol). Optical purity: 99.0%.

EXAMPLE 2 Resolution by methods (b) and (c)

To a solution of 85 gr of .[.4-(4-dimethylamino)-1-4'-fluorophenyl)-1-(hydroxybutyl)-3-(hydroxymethyl)-benzonitrile.]. .Iadd.4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxy-1-butyl]-3-(hydroxymethyl)-benzonitrile.Iaddend., hydrobromide in 500 ml of water were added 200 ml of ice cooled 2M NaOH solution and 500 ml of ether. The mixture was stirred for 1/2 hour, the ether phase separated, dried (MgSO4) and the ether evaporated. The remaining oil was dissolved in 400 ml of 2-propanol at 40 C., and 40 gr of (+)-di-p-.[.toloyltartaric.]..Iadd.toluoyltartaric .Iaddend.acid (as hydrate) were added under vigorous stirring. After a short while crystallization began. After 3 hours of stirring the precipatated salt was filtered off and dried yielding 29.2 gr (55.1%) of .[.(-)-4-(4-dimethylamino)-1-(4'fluorophenyl)-1-(hydroxybutyl)- 3-(hydroxymethyl)benzonitrile.]. .Iadd.(-)-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxy-1-butyl]-3-(hydroxymethyl)benzonitrile.Iaddend., hemi (+)-di-p-.[.toloyltartaric.]. .Iadd.toluoyltartaric .Iaddend.acid salt. MP: 134-135 C., [α]D =+10.0 (c=1, CH3 OH). The filtrate is used below.

To an ice cooled solution of 14 gr of the (-)-isomer from above as a base in 300 ml of dry toluene were added 16 ml of triethylamine, and 3.6 ml of methansulfonyl chloride in 20 ml of dry toluene were added dropwise during 10 minutes. The reaction mixture was further stirred for 1/2 hour, washed with brine, dried (MgSO4) and the solvent evaporated. The title compound was purified by column chromatography affording 8 g of (+)-1-(3-dimethylaminopropyl)-1-(4'-.[.flurophenyl.]. .Iadd.fluorophenyl.Iaddend.-1,3-dihydroisobenzofuran-5-carbonitrile. [α]D =+12.33 (c=1, CH3 OH). The oxalic acid salt of the (+)-isomer crystallized from acetone. MP: 147-148 C., [α]D =+12.31 (c=1, CH3 OH).

The pamoic acid salt of the (+)-isomer was prepared in the following manner: To 1.8 g of the base of the (+)-isomer was added 2 g of pamoic acid in 25 ml of MeOH. The mixture was refluxed for an hour and subsequently colled to room temperature. The precipitate was filtered off yielding 3.0 g of the pamoic acid salt. MP: 264-266 C., [α]D =+13.88 C. (c=1, dimethylformamide).

A 2:1 addition compound of the (+)-isomer with L(+)-tartaric acid was prepared in the following manner: 4 g of the (+)-isomer as base were dissolved in 100 ml of diethyl ether and extracted into 100 ml of water containing 0.8 g of L(+)-tartaric acid by stirring. The organic phase was separated and discarded. The water-phase was freeze-dried in vacuo (<0.1 mm Hg) for 18 hours leaving 3.8 g of a white powder of the title compound. This addition compound was stable and not hygroscopic.

In a corresponding manner as above via the .[.(+)-4-(4-dimethylamino)-1-(4'-fluorophenyl)-1-(hydroxybutyl)-3-(hydroxymethyl)benezonitrile.]. .Iadd.(+)-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxy-1-butyl]-3-(hydroxymethyl)-benzonitrile.Iaddend., hemi (-)-di-(p-toloyl)tartaric acid salt ([α]D =-8.9 (c=1, CH3 OH)) which was converted to the corresponding diol base ([α]D =+61.1 (c=1, CH3 OH)) and finally ringclosure reaction yielded 10 gr of (-)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile. [α]D =-12.1 (c=1, CH3 OH).

The oxalic acid salt of the (-)-isomer crystallized from acetone, MP: 147-148 C., [α]D =-12.08 (c=1, CH3 OH).

EXAMPLE 3 Preparation of citalopram by method (c)

To an ice cooled solution of 28 gr of racemic diol base, II, in 500 ml of dichloromethane were added 32 ml of triethylamine, and 7.5 ml of methansulfonyl chloride in 30 ml of dichloromethane were added dropwise during a half hour. The reaction mixture was washed with 0.1M NaOH solution twice, the organic phase separated, dried (MgSO4) and the solvent evaporated, leaving 21.5 gr of the title ()-citalopram as a crystalline base. The thus obtained material was dissolved in a mixture of 2-propanol and methanol (2:1) and an equivalent amount of gaseous HBr was introduced. The mixture was left overnight and the precipitated hydrobromide was filtered off. Yield: 26 gr with MP 184-186 C.

The enantiomers from Example 1 were tested for their ability to block 5-HT reuptake in standard and reliable test method. Results are shown in Table I in comparison with the racemic mixture of citalopram.

5-HTP-POTENTIATION

The test evaluates the ability of the substance to potentiate the effect of 5-HTP, which results in development of 5-HT syndrome (Christensen, Fjalland, Pedersen, Danneskiold-Samsoe and Svendsen; European J. Pharmacol. 41, 153-162, 1977).

Procedure

Each treatment group consists of 3 mice, and two groups are treated with the highest test dose. A control group only treated with 5-HTP is included and a group treated with citalopram 10 mg/kg and 5-HTP is used as reference for full 5-HT syndrome.

The Route of Administration

30 minutes after the administration of the test substance, the other groups are given 5-HTP (100 mg/kg) i.v. (injection time 5-10 sec.). After this 5-HTP dose normal, untreated mice remain unaffected, but if the animals have been pretreated with a substance, which inhibits the uptake of 5-HT or a 5-HT agonist, a 5-HTP syndrome will occur. The symptoms are the same as previously described: (1) excitation, (2) tremor, and (3) abduction of the hind limbs. The animals are observed for 15 minutes and each animal is given one point for each symptom present. Again the result is stated in fractions: 0/9, 1/9, . . . 9/9, where 0, 1, . . . , 9 are the number of points per group after the dose in question. The ED50 value is calculated by log-probit analysis.

INHIBITION OF 3 H-SEROTONIN UPTAKE IN RAT BRAIN SYNAPTOSOMES

By this method the inhibition by drugs of the uptake of .[.3 H-serotonin.]. .Iadd.3 H-serotonin .Iaddend.(3 H-5-HT)(10 nm) in rat brain synaptosomes is determined in vitro. Method and results in Hyttel, Psychopharmacology 1978, 60, 13-18; Hyttel, Prog. Neuro-Psychopharmacol. & Biol. .[.Psychait..]. .Iadd.Psychiat. .Iaddend.1982, 6,277-295; Hyttel & Larsen, Acta pharmacol. tox. 1985, 56, suppl. 1, 146-153. .[.Procedure p.].

.Iadd.Procedure .Iaddend.

Male Wistar (Mol: Wist) rats (125-250 g) are sacrified by decapitation and .[.exanguinated.]. .Iadd.exsanguinated .Iaddend.Brain tissue (minus cerebellum) is gently homogenized (glass teflon homogenizer) in 40 vol (w/v) of ice cold 0.32M of sucrose containing 1 mM of nialamide. The P2 fraction (synaptosomal fraction) is obtained by centrifugation (600 g. 10 min and 25000 g. 55 min, 4 C.) and suspended in 800 volumes of a modified Krebs-Ringer-phosphate buffer, pH 7.4.

To 4000 μl of the synaptosomal suspension (5 mg original tissue) on ice are added 100 μl test substance in water. After preincubation at 37 C. for 5 min, 100 μl of 3 H-1-NA (final .[.concnetration.]. .Iadd.concentration .Iaddend.10 nM) are added and the samples are incubated for 10 min at 37 C. The incubation is terminated by filtering the samples under vacuum through .[.Whatmam.]. .Iadd.Whatman .Iaddend.GF/F filters with a wash of 5 ml buffer containing 10 μM of unlabeled 5-HT. The filters are placed in counting vitals and 4 ml of appropriate scintillation fluid (e.g. Picofluor 15) are added. After shaking for 1 h and storage 2 h in the dark the content of radioactivity is determined by liquid scintillation counting. Uptake is obtained by subtracting the nonspecific binding and passive transport measured in the presence of 10 μM citalopram (Lu 10-171-B).

For determination of the inhibition of uptake five concentrations of drugs covering 3 decades are used.

The measured cpm are plotted against drug concentration on semilogarithmic paper, and the best fitting s-shaped curve is drawn. The IC50 -value is determined as the concentration, at which the uptake is 50% of the total uptake in control samples minus the nonspecific binding and uptake in the presence of 10 μM of citalopram.

              TABLE 1______________________________________PHARMACOLOGICAL TEST RESULTS______________________________________       5-HTP pot.    5-HT uptake inhibitionCompound    ED50 μmol/kg                     IC50 (nM)______________________________________(+)-citalopram       2.0           1.1(-)-citalopram       120           150()-citalopram       3.3           1.8______________________________________

(+)-1-(3-Dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile ((+)-citalopram) and the non-toxic acid addition salts thereof may be administered to animals such as dogs, cats, horses, sheeps or the like, including human beings, both orally and parenterally, and may be used for example in the form of tablets, .[.capsles.]. .Iadd.capsules.Iaddend., powders, syrups or in the form of the usual .[.sterial.]. .Iadd.sterile .Iaddend.solutions for injection. .[.Results upon administration to human being have been very gratifying..].

Most conveniently the compounds of Formula I are administered orally in unit dosage form such as tablets or capsules, each dosage unit containing the free amine or a non-toxic acid addition salt of one of the said compounds in .[.a.]. .Iadd.an .Iaddend.amount of from about 0.10 to about 100 mg, most preferably, however, from about b 5 to 50 mg, calculated as the free amine, the total daily dosage usually ranging from about 1.0 to about 500 mg. The exact individual dosages as well as daily dosages in a particular case will, of course, be determined according to established medical principles under the direction of a physician.

When preparing tablets, the .[.acitve.]. .Iadd.active .Iaddend.ingredient is for the most part mixed with ordinary tablet adjuvants such as corn starch, potato starch, talcum, magnesium stearate, gelative, lactose, gums, or the like.

Typical examples of formulas for .[.composition.]. .Iadd.compositions .Iaddend.containing (+)-citalopram in the form of an acid addition salt as the active ingredient, are as follows:

______________________________________(1) Tablets containing 5 milligrams of (+)-citalopramcalculated as the free base:Compound 20                 5      mgLactose                     18     mgPotato starch               27     mgSaccharose                  58     mgSorbitol                    3      mgTalcum                      5      mgGelatine                    2      mgPovidone                    1      mgMagnesium stearate          0.5    mg(2) Tablets containing 50 milligrams of (+)-citalopramcalculated as the free base:(+)-citalopram              50     mgLactose                     16     mgPotato starch               45     mgSaccharose                  106    mgSorbitol                    6      mgTalcum                      9      mgGelatine                    4      mgPovidone                    3      mgMagnesium stearate          0.6    mg(3) Syrup containing per milliliter:(+)-citalopram              10     mgSorbitol                    500    mgTragacanth                  7      mgGlycerol                    50     mgMethyl-paraben              1      mgPropyl-paraben              0.1    mgEthanol                     0.005  mlWater ad                    1      ml(4) Solution for injection containing per milliliter:(+)-citalopram              50     mgAcetic acid                 17.9   mgSterile water ad            1      ml(5) Solution for injection containing per milliliter:(+)-citalopram              10     mgSorbitol                    42.9   mgAcetic acid                 0.63   mgSodium hydroxide            22     mgSterile water ad            1      ml______________________________________

Any other pharmaceutical tableting adjuvants may be used provided that they are compatible with the active ingredient, and additional compositions and dosage forms may be similar to those presently used for neuroleptics, analgesics or antidepressants.

Also combinations of (+)-citalopram as well as its non-toxic acid salts with other active ingredients, especially other neuroleptics, thymoleptics, tranquilizers, analgetics or the like, fall within the scope of the present invention.

As previously stated, when isolating the enantiomers of citalopram in the form of an acid addition salt the acid is preferably selected so as to contain an anion which is non-toxic and pharmacologically acceptable, at least in usual therapeutic doses. Representative salts which are included in this preferred group are the hydrochlorides, hydrobromides, sulphates, acetates, phosphates, nitrates, methanesulphonates, ethane-sulphonates, lactates, citrates, tartrates or bitartrates, pamoates and maleates of the amines of Formula I. Other acids are likewise suitable and may be employed if desired. For example: fumaric, benzoic, ascorbic, succinic, salicylic, bismethylenesalicylic, propionic, gluconic, malic, malonic, mandelic, .[.cannamic.]. .Iadd.cinnamic.Iaddend., citraconic, stearic, palmitic, itaconic, glycolic, benzenesulphonic, and sulphamic acids may .[.be .]. also be employed as acid addition salt-forming acids.

When it is desired to isolate a compound of the invention in the form of the free base, this may be done according to conventional procedure as by dissolving the isolated or unisolated salt in water, treating with a suitable alkaline material, extracting the liberated free base with a suitable organic .[.solvent.]. .Iadd.solvent,.Iaddend.drying the extract and evaporating to dryness or fractionally distilling to effect isolation of the free basic amine.

The invention also comprises a method for the alleviation, palliation, mitigation or inhibition of the manifestations of certain physiological-psychological .[.abnormalies.]. .Iadd.abnormalities .Iaddend.of animals, especially depressions.Iadd., .Iaddend.by administering to a living animal body, including human beings, an adequate quantity of (+)-citalopram or a non-toxic acid addition salt thereof. An adequate quantity would be from about 0.001 mg to about 10 mg per kg of body weight in each unit dosage, and from about 0.003 milligrams to about 7 milligrams/kg of body weight per day.

It is to be understood that the invention is not limited to the exact details of operation or exact .[.compound.]. .Iadd.compounds .Iaddend.or compositions shown and described, as obvious modifications and equivalents will be apparent to one skilled in the art.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US4136193 *Jan 7, 1977Jan 23, 1979Kefalas A/SAnti-depressive substituted 1-dimethylaminopropyl-1-phenyl phthalans
US4650884 *Aug 2, 1985Mar 17, 1987H. Lundbeck A/SNovel intermediate and method for its preparation
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US6579993Jan 30, 2002Jun 17, 2003Orion Corporation, FermionProcess for the preparation of 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
US6753433Feb 24, 2003Jun 22, 2004Orion Corporation, FermionProcess for the preparation of 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
US6960613Aug 20, 2003Nov 1, 2005H. Lundbeck A/STreatment of neurotic disorders
US7019153Jun 8, 2004Mar 28, 2006Sun Pharmaceutical Industries LimitedProcess for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran acetamido-3-substituted-3-cephem-4-carboxylic acid
US7148364Jan 7, 2003Dec 12, 2006Sun Pharmaceutical IndustriesProcess for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile
US7192939Jan 30, 2003Mar 20, 2007Montana State UniversityPestalotiopsis microsporia isolates and compounds derived therefrom
US7265151Aug 7, 2003Sep 4, 2007H. Lundbeck A/STreatment of neurotic disorders
US7365095Apr 21, 2006Apr 29, 2008WyethChromane and chromene derivatives and uses thereof
US7368477Apr 21, 2006May 6, 2008WyethBenzofuranyl alkanamine derivatives and uses thereof
US7402687Apr 21, 2006Jul 22, 2008WyethDihydrobenzofuran derivatives and uses thereof
US7420068Sep 23, 2004Sep 2, 2008H. Lundbeck A/SCrystalline composition containing escitalopram
US7560576Jul 14, 2009H. Lundbeck A/SCrystalline base of escitalopram and orodispersible tablets comprising escitalopram base
US7566793Apr 22, 2008Jul 28, 2009Synthon BvProcess for resolving citalopram
US7569605Oct 16, 2006Aug 4, 2009Forest Laboratories Holdings LimitedMethods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
US7582780Feb 2, 2005Sep 1, 2009H. Lundbeck A/SMethod for the separation of intermediates which may be used for the preparation of escitalopram
US7723533Mar 12, 2008May 25, 2010H. Lundbeck A/SCrystalline base of escitalopram and orodispersible tablets comprising escitalopram base
US7790935Aug 12, 2005Sep 7, 2010Sun Pharma Global FzeProcess for preparation of citalopram and enantiomers
US7834201Jun 21, 2006Nov 16, 2010H. Lundbeck A/SCrystalline base of escitalopram and orodispersible tablets comprising escitalopram base
US7939680Jul 20, 2006May 10, 2011Aurobindo Pharma Ltd.Process for the preparation of Escitalopram
US7964742Jun 10, 2010Jun 21, 2011Sun Pharma Global FzeProcess for preparation of citalopram and enantiomers
US7989645Aug 2, 2011Sun Pharma Global FzeProcess for preparation of citalopram and enantiomers
US8829020Jul 16, 2010Sep 9, 2014Mallinckrodt LlcCompounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
US20030130527 *Feb 24, 2003Jul 10, 2003Orion Corporation FermionProcess for the preparation of 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
US20040009573 *Jan 30, 2003Jan 15, 2004Gary StrobelPestalotiopsis microsporia isolates and compounds derived therefrom
US20040029956 *Aug 7, 2003Feb 12, 2004H. Lundbeck A/STreatment of neurotic disorders
US20040132808 *Dec 19, 2003Jul 8, 2004Hans PetersenCrystalline base of citalopram
US20040167210 *Dec 30, 2003Aug 26, 2004Hans PetersenCrystalline base of citalopram
US20040192764 *Aug 20, 2003Sep 30, 2004H. Lundbeck A/SUse of enantiomeric pure escitalopram
US20040192766 *Aug 20, 2003Sep 30, 2004H. Lundbeck A/SUse of enantiomeric pure escitalopram
US20040198809 *May 1, 2002Oct 7, 2004Connie SanchezUse of enantiomeric pure escitalopram
US20040198811 *Aug 20, 2003Oct 7, 2004H. Lundbeck A/SUse of enantiomeric pure escitalopram
US20050043550 *Jan 7, 2003Feb 24, 2005Thennati RajamannarProcess for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile
US20050101665 *Aug 20, 2003May 12, 2005H. Lundbeck A/STreatment of neurotic disorders
US20050101666 *Nov 8, 2004May 12, 2005H. Lundbeck A/SMethod of treating premenstrual dysphoric disorder with escitalopram
US20050143350 *Nov 18, 2004Jun 30, 2005Seed John C.Combination drug therapy to treat obesity
US20050165092 *Mar 24, 2005Jul 28, 2005H. Lundbeck A/SCrystalline base of citalopram
US20050196453 *May 21, 2004Sep 8, 2005H. Lundbeck A/SCrystalline composition containing escitalopram
US20060014957 *Jul 1, 2005Jan 19, 2006Pfizer IncResolution of an aryl-fused azapolycyclic compound
US20060247276 *Apr 21, 2006Nov 2, 2006WyethBenzofuranyl alkanamine derivatives and uses thereof
US20060258714 *Apr 21, 2006Nov 16, 2006WyethChromane and chromene derivatives and uses thereof
US20060258739 *Apr 21, 2006Nov 16, 2006WyethDihydrobenzofuran derivatives and uses therof
US20070021499 *Jun 21, 2006Jan 25, 2007H. Lundbeck A/SCrystalline base of escitalopram and orodispersible tablets comprising escitalopram base
US20070112075 *Oct 16, 2006May 17, 2007Forest Laboratories, Inc.Stable pharmaceutical formulations containing escitalopram and bupropion
US20070123584 *Jan 22, 2007May 31, 2007H. Lundbeck A/SMethod of treating premenstrual dysphoric disorder with escitalopram
US20070190624 *Feb 2, 2005Aug 16, 2007H. Lundbeck A/SMethod for the separation of intermediates which may be used for the preparation of escitalopram
US20070203231 *Oct 16, 2006Aug 30, 2007Forest Laboratories, Inc.Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
US20070225279 *Mar 23, 2007Sep 27, 2007WyethTherapeutic combinations for the treatment of depression
US20080153808 *Dec 12, 2007Jun 26, 2008Allergan, Inc.Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
US20080153825 *Dec 12, 2007Jun 26, 2008Allergan Inc.Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders
US20080153832 *Dec 12, 2007Jun 26, 2008Allergan, Inc.Pan-alpha-2 receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
US20080153874 *Dec 12, 2007Jun 26, 2008Allergan Inc.Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US20080153880 *Dec 12, 2007Jun 26, 2008Allergan, Inc.Pan-alpha-2 receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20080153881 *Dec 12, 2007Jun 26, 2008Allergan, Inc.Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20080153927 *Dec 11, 2007Jun 26, 2008Allergan, Inc.Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
US20080161388 *Mar 12, 2008Jul 3, 2008H. Lundbeck A/SCrystalline base of escitalopram and orodispersible tablets comprising escitalopram base
US20080161584 *Mar 12, 2008Jul 3, 2008H. Lundbeck A/SCrystalline base of escitalopram and orodispersible tablets comprising escitalopram base
US20080177096 *Feb 1, 2008Jul 24, 2008Sun Pharmaceutical Industries Ltd.Process for preparation of citalopram and enantiomers
US20080182891 *Mar 19, 2008Jul 31, 2008WyethChromane and chromene derivatives and uses thereof
US20080200541 *Apr 18, 2008Aug 21, 2008WyethBenzofuranyl Alkanamine Derivatives and Uses Thereof
US20080281110 *Apr 22, 2008Nov 13, 2008Jie ZhuProcess for resolving citalopram
US20090036468 *Aug 4, 2008Feb 5, 2009Forest Laboratories Holdings LimitedPharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
US20090099375 *Jul 20, 2006Apr 16, 2009Vipin Kumar Kaushikprocess for the preparation of escitalopram
US20100249437 *Jun 10, 2010Sep 30, 2010Sun Pharma Global FzeProcess for preparation of citalopram and enantiomers
US20100249438 *Sep 30, 2010Vijaya Bhaskar BolugodduPreparation of escitalopram
US20110015208 *Sep 27, 2010Jan 20, 2011Gary SamoriskiPharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
EP1988086A1Apr 22, 2008Nov 5, 2008Synthon B.V.Process for resolving citalopram via its (S)-enriched citalopram tartrate compound.
EP2141156A1Aug 12, 2005Jan 6, 2010Sun Pharma Global FZEProcess for Preparation of Citalopram and Enantiomers
WO2006021971A2Aug 12, 2005Mar 2, 2006Sun Pharmaceutical Ind Ltd'process for preparation of citalopram and enantiomers'
WO2013114416A1Jan 30, 2013Aug 8, 2013Carthesia S.A.S.Lyophilized tablets of escitalopram oxalate for sublingual administration
Classifications
U.S. Classification514/469, 558/422, 549/467
International ClassificationA61K31/34, A61P25/24, A61P3/04, A61P3/00, C07B57/00, C07D307/78, C07D, A61P25/30, A61K31/00, C07C255/58, A61P25/26, C07C, A61K31/343, C07D307/00, C07C309/00, C07C255/00, C07C303/00, C07C255/54, C07C255/59, C07D307/87
Cooperative ClassificationC07D307/87
European ClassificationC07D307/87
Legal Events
DateCodeEventDescription
Jan 23, 1998FPAYFee payment
Year of fee payment: 8
Jan 23, 2002FPAYFee payment
Year of fee payment: 12
Oct 11, 2002PTEF
Free format text: PRODUCT NAME: LEXAPRO (ESCITALOPRAM OXALATE); REQUESTED FOR 827 DAYS
Filing date: 20021011
Expiry date: 20090608
Oct 6, 2006PTEG
Free format text: PRODUCT NAME: LEXAPRO (ESCITALOPRAM OXALATE)
Filing date: 20021011
Expiry date: 20090608